December 14, 2021 Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
November 3, 2021 Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
October 26, 2021 Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021
October 21, 2021 Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase
October 6, 2021 Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
September 21, 2021 Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
August 5, 2021 Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
August 3, 2021 Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital
July 28, 2021 Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021
June 29, 2021 Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial
